- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Khleif on Next Steps to Take With Immunotherapy
April 19th 2016, 2:58pm
Samir N. Khleif, MD, director, GRU Cancer Center, discusses next steps researchers and physicians need to take with immunotherapy in the field of oncology.
Using Multiple Biomarkers Improves Risk Prediction for Breast Cancer
April 19th 2016, 1:54pm
The addition of three biological markers to conventional breast cancer risk models significantly improved the ability to distinguish women at high and low risk.
Frontline Pembrolizumab Induces Durable Responses in Merkel Cell Carcinoma
April 19th 2016, 12:02pm
Anti–PD-1 therapy in the first-line induced responses in more than half of patients with advanced Merkel cell carcinoma, with encouraging durability to the responses.
Dr. Berger on Noninvasive Screening Tool for CRC
April 19th 2016, 10:00am
Barry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses a study demonstrating the benefit of utilization of the Cologuard screening test for colorectal cancer (CRC).
Dr. DeMichele on the I-SPY2 Trial for HER2+ Breast Cancer
April 19th 2016, 8:00am
Angela M. DeMichele, MD, professor of Medicine and Epidemiology, University of Pennsylvania, discusses results of the HER2-positive breast cancer cohort of the phase II ISPY-2 trial, which investigated the neoadjuvant combinations of ado-trastuzumab emtansine (T-DM1) and pertuzumab (Perjeta) versus paclitaxel (Abraxane) and trastuzumab (Herceptin).
Nivolumab Doubles 1-Year OS Rates in Head and Neck Cancer
April 19th 2016, 7:32am
Treatment with single-agent nivolumab reduced the risk of death by 30% and double 1-year overall survival rates compared investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.
Dr. Fred Hirsch on Next Steps for Necitumumab in NSCLC
April 19th 2016, 6:55am
Fred R. Hirsch, MD, PhD, professor of medicine and pathology, University of Colorado Cancer Center, CEO, International Association for the Study of Lung Cancer (IASLC), discusses necitumumab for first-line treatment of advanced squamous non-small cell lung cancer (NSCLC).
PD-L1 Expression Assays Show Similar Performance for NSCLC
April 19th 2016, 6:08am
Three currently available assays for PD-L1 expression exhibited a high degree of correlation in a comparative study involving archived lung cancer tissue.
Neoadjuvant T-DM1 Plus Pertuzumab Shows Promise for HER2-Positive Breast Cancer
April 18th 2016, 2:42pm
The combination of ado-trastuzumab emtansine and pertuzumab was superior to the combination of paclitaxel and trastuzumab as neoadjuvant treatment for women with HER2-positive breast cancer.
PARP/AKT Inhibitor Combination Active in Multiple Tumor Types
April 18th 2016, 2:30pm
The combination of the PARP inhibitor olaparib and the investigational AKT inhibitor AZD5363 resulted in durable responses in patients with solid tumors, with and without BRCA mutations.
Two Genetic Variants May Signal Which Survivors Are at Highest Risk for Breast Cancer After Chest Radiation
April 18th 2016, 1:46pm
Chest radiotherapy to treat a childhood cancer is a well-established risk factor for developing breast cancer in adulthood
Palbociclib Showed Antiproliferative Activity in Early-stage Breast Cancer
April 18th 2016, 12:52pm
Palbociclib may have antiproliferative effects when used as a neoadjuvant therapy for women with early stage breast cancer.
70-Gene Signature Identifies Breast Cancer Subgroup Unlikely to Benefit From Adjuvant Chemo
April 18th 2016, 11:20am
A 70-gene signature (MammaPrint) demonstrated a high level of accuracy at identifying a large subset of women with clinically high-risk early stage breast cancer for whom adjuvant chemotherapy was unlikely to produce benefit.
Dr. Postow on OS Results of CheckMate-069 Study
April 18th 2016, 7:32am
Michael Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the overall survival (OS) results of the CheckMate-069 study, which investigated the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.
Nivolumab/Ipilimumab Combination Shows Survival Benefit in Advanced Melanoma
April 18th 2016, 7:18am
The combination of ipilimumab (Yervoy) and nivolumab (Opdivo) showed a 42% improvement in overall survival compared with ipilimumab monotherapy for patients with advanced melanoma in a 2-year assessment of the phase II CheckMate-069 trial.
Yong-Chen William Lu on Adoptive T-Cell Therapy in Solid Tumors
April 18th 2016, 6:02am
Yong-Chen William Lu, PhD, a fellow in the Surgery Branch of the National Cancer Institute, discusses a CD4 T-cell immunotherapy targeting MAGE-A3 that is showing early clinical responses in patients with metastatic cancer.
Dr. Lai on Risk Factors Associated With Glioma
April 17th 2016, 1:18pm
Rose K. Lai, MD, clinical associate professor of Neurology, University of Southern California, discusses results of the Glioma International Case Control study.
Entrectinib Achieves High Response Rate Across Solid Tumors
April 17th 2016, 1:07pm
Treatment with the novel multikinase inhibitor entrectinib achieved objective responses in 79% of patients with solid tumors associated with NTRK, ROS-1, or ALK rearrangements.
MAGE-A3—Targeted Adoptive T-Cell Therapy Shows Promise in Solid Tumors
April 17th 2016, 12:41pm
A form of immunotherapy that harnesses the power of CD4 T-cells was shown to be safe and effective in patients with various types of metastatic cancers.
Dr. Hodi on Long-Term Survival Data for Nivolumab in Melanoma
April 17th 2016, 11:56am
F. Stephen Hodi, MD, director of the Melanoma Center at Dana-Farber Cancer Institute, discusses the results of the longest follow-up survival study of patients with advanced melanoma who were treated with single-agent nivolumab (Opdivo).